764 related articles for article (PubMed ID: 16972282)
1. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z; Bates M; Madura JD
Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
[TBL] [Abstract][Full Text] [Related]
2. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
Gandhi NS; Freeman C; Parish CR; Mancera RL
Glycobiology; 2012 Jan; 22(1):35-55. PubMed ID: 21746763
[TBL] [Abstract][Full Text] [Related]
3. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
4. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
5. Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.
Ferrari AM; Degliesposti G; Sgobba M; Rastelli G
Bioorg Med Chem; 2007 Dec; 15(24):7865-77. PubMed ID: 17870536
[TBL] [Abstract][Full Text] [Related]
6. Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of alpha-glucosidase inhibitors.
Bharatham K; Bharatham N; Park KH; Lee KW
J Mol Graph Model; 2008 Jun; 26(8):1202-12. PubMed ID: 18096420
[TBL] [Abstract][Full Text] [Related]
7. Homology modeling of human sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: hints for the design of selective NEU3 inhibitors.
Magesh S; Suzuki T; Miyagi T; Ishida H; Kiso M
J Mol Graph Model; 2006 Oct; 25(2):196-207. PubMed ID: 16427342
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of activation of human heparanase investigated by protein engineering.
Nardella C; Lahm A; Pallaoro M; Brunetti M; Vannini A; Steinkühler C
Biochemistry; 2004 Feb; 43(7):1862-73. PubMed ID: 14967027
[TBL] [Abstract][Full Text] [Related]
9. Molecular model of human heparanase with proposed binding mode of a heparan sulfate oligosaccharide and catalytic amino acids.
Sapay N; Cabannes E; Petitou M; Imberty A
Biopolymers; 2012 Jan; 97(1):21-34. PubMed ID: 21780097
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors.
Bharatham N; Bharatham K; Lee KW
J Mol Graph Model; 2007 Mar; 25(6):813-23. PubMed ID: 16996282
[TBL] [Abstract][Full Text] [Related]
11. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
[TBL] [Abstract][Full Text] [Related]
12. Receptor flexibility in de novo ligand design and docking.
Alberts IL; Todorov NP; Dean PM
J Med Chem; 2005 Oct; 48(21):6585-96. PubMed ID: 16220975
[TBL] [Abstract][Full Text] [Related]
13. Why does beta-secretase zymogen possess catalytic activity? Molecular modeling and molecular dynamics simulation studies.
Zuo Z; Gang C; Zou H; Mok PC; Zhu W; Chen K; Jiang H
Comput Biol Chem; 2007 Jun; 31(3):186-95. PubMed ID: 17500040
[TBL] [Abstract][Full Text] [Related]
14. A multistep approach to structure-based drug design: studying ligand binding at the human neutrophil elastase.
Steinbrecher T; Case DA; Labahn A
J Med Chem; 2006 Mar; 49(6):1837-44. PubMed ID: 16539369
[TBL] [Abstract][Full Text] [Related]
15. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
16. Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
Gozalbes R; Mosulén S; Ortí L; Rodríguez-Díaz J; Carbajo RJ; Melnyk P; Pineda-Lucena A
Bioorg Med Chem; 2013 Apr; 21(7):1944-51. PubMed ID: 23415087
[TBL] [Abstract][Full Text] [Related]
17. Docking ligands onto binding site representations derived from proteins built by homology modelling.
Schafferhans A; Klebe G
J Mol Biol; 2001 Mar; 307(1):407-27. PubMed ID: 11243828
[TBL] [Abstract][Full Text] [Related]
18. Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target-based approach.
Charlier C; Hénichart JP; Durant F; Wouters J
J Med Chem; 2006 Jan; 49(1):186-95. PubMed ID: 16392803
[TBL] [Abstract][Full Text] [Related]
19. Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase.
Venkatarangan P; Hopfinger AJ
J Med Chem; 1999 Jun; 42(12):2169-79. PubMed ID: 10377222
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.
Pala D; Rivara S; Mor M; Milazzo FM; Roscilli G; Pavoni E; Giannini G
Glycobiology; 2016 Jun; 26(6):640-54. PubMed ID: 26762172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
